medigraphic.com
ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2014, Number 2

<< Back Next >>

Acta Med Cent 2014; 8 (2)

Results of treatment with Heberprot -P patients with a diagnosis of diabetic foot in the Municipality of Ranchuelo

Bustillo SMJ, Feitó CTR, García SFV, Álvarez LY, Guerra DBM

Language: Spanish
References: 20
Page: 16-22
PDF size: 134.71 Kb.


ABSTRACT

Introduction: the diabetic foot syndrome is one of the chronic complications of increased morbidity and disability in diabetic patients today. High rates of amputations cause a significant degree of disability with high economic and social cost. It has been shown that administration of Heberprot-P stimulates the formation of granulation tissue in the ulcer bed and closed by second intention.
Objective: to describe the results of treatment with Heberprot-P in patients with a diagnosis of diabetic foot.
Material and methods: a prospective study of 86 patients with diagnosis of diabetic foot in the period January 2010 to December 2013 at the Policlinic “Juan Contreras B. Fowler” in Ranchuelo Municipality, in the Province of Villa Clara, which were applied to the epidermal growth factor intralesionally. Patients taking into account age, sex, personal medical history, the severity depending on the classification of Wagner, the dose and the number of applications, the assessment of response and adverse effects were studied.
Results: in the studied series predominated patients aged between 50 and 59 years old (26.74%), females (52.33%) and diabetes type 2; the number of applications was increased in the plantar ulcer grade III; full granulation was achieved in 70 % of cases and partial in 24.4%; there was major amputation in two patients with adverse effects and they presented pain and burning.
Conclusions: with the implementation of Heberprot-P has been achieved a favorable outcome in most cases and it is able to maintain the integrity of the member and its functionality in most patients.


REFERENCES

  1. Marinello Roura J, Blanes Mompó I, Escudero Rodríguez JR, Ibáñez Esquembre V, Rodríguez Olay J. Tratado de Pie Diabético. Barcelona: Centro de Documentación del Grupo Esteve; 2002.

  2. American Diabetes Association. Position Statement: Standards of Medical Care in Diabetes. Diabetes Care. 2007;30(Suppl 1):S4-S41.

  3. Conesa González AJ, Diaz Diaz O, Conesa del Rio JR, Domínguez Alonso JE. Mortalidad por Diabetes mellitus y sus complicaciones. Ciudad de la Habana, 1990-2002. Rev Cub Endocrinol. 2010;21(1):35-50.

  4. Ministerio de Salud Pública. Mortalidad por Diabetes mellitus. Anuario Estadístico de Salud 2011. La Habana: Dirección Nacional de Registros Médicos y Estadísticas de Salud; 2012.

  5. Crawford JM, Cotran RS. El páncreas endocrino. En: Cotran RS, Kumar V, Collins T. Robbins Patología Estructural y Funcional. 7 ed. Madrid: Elsevier; 2004ma. p. 951-66.

  6. González Fernández R, Crespo NV, Crespo M. Características clínicas de la diabetes mellitus en un área de salud. Rev Cubana Med Gen Integr [Internet]. 2000 [citado 12 Mar 2013];16(2):[aprox. 11 p.]. Disponible en: http://bvs.sld.cu/revistas/mgi/vol16_2_00/mgi07200.htm

  7. Meaney B. Diabetic foot care: prevention is better than cure. J Ren Care 2012;38 Suppl 1:90-8. doi: 10.1111/j.1755-6686.2012.00276.x.

  8. Sun JH, Tsai JS. Risk factors for lower extremity amputation in diabetic foot disease categorized by Wagner classification. Diabetes Res Clin Pract. 2012; 95(3):358-63.

  9. Gimeno Orna JA, Boned Juliani B, Lou Arnal LM, Castro Alonso FJ. Factores relacionados con el control glucémico de pacientes con diabetes tipo 2. An Med Interna (Madrid). 2003;20:122-6.

  10. Bekker-Mendez C, Guzman-Aguilar RM. TUNEL-positive cells in the surgical border of an amputation due to infected diabetic foot." Mol Med Report. 2012;5(2):363-72.

  11. Alexiadou K, Doupis J. Management of diabetic foot ulcers. Diabetes Ther 2012;3(1):4. doi: 10.1007/s13300-012-0004-9. PMCID: PMC3508111.

  12. Velázquez W, Valles A. Impacto del Heberprot-P en el tratamiento de las úlceras del pie diabético. Biotecnol Apl. 2010;27:129-35.

  13. Valdés J. "Physiological study in Saccharomyces cerevisiae for overproduction of a homogeneous human epidermal growth factor molecule.” Biotecnol Apl [Internet]. 2009 [citado 12 Mar 2013];26(2): [aprox. 7 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1027-28522009000200010

  14. Balingit PP, Armstrong DG. NorLeu(3) -A(1-7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial." Wound Repair Regen. 2012;20(4):482-90.

  15. Fernandez-Montequın JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Gala´ n-Naranjo K, Ramı´rez-Navas M, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009;6(1):67–72. doi: 10.1111/j.1742-481X.2008.00561.x ...

  16. Bolívar Y, Mena M, Brito S, Fernández M, Chacín B, Lares M, et al. Evaluación y seguimiento de los pacientes de la unidad de Pie Diabético del departamento de endocrinología del hospital militar Dr. Carlos Arvelo y su comparación con estándares internacionales. Rev Ven Endocrinol Metabol [Internet]. 2010 Jun [citado 12 Mar 2013];8(2): [aprox. 5 p.]. Disponible en: http://www.scielo.org.ve/scielo.php?script=sci_arttext&pid=S1690-31102010000200005&lng=pt&nrm=iso

  17. Margolis DJ, Malay DS, Hoffstad OJ. Prevalence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medicare beneficiaries, 2006 to 2008: Data Points #1. Data Points Publication Series [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 [actualizado 17 Feb 2011; citado 12 Mar 2013]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK63602/

  18. Rivero F. Experiencias del Programa de atención integral a pacientes con pie diabético en el estado Zulia, Venezuela. Biotecnol Apl [Internet]. 2010 Abr-Jun [citado 12 Mar 2013];27(2): [aprox. 3 p.]. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1027-28522010000200004&script=sci_arttext

  19. Monteiro-Soares M, Boyko J, Ribeiro J, Ribeiro I, Dinis-Ribeiro M. Risk stratification systems for diabetic foot ulcers: a systematic review. Diabetología. 2011;54:1190–9.

  20. Fernández-Montequín JI, Mena G. Tratamiento y recuperación del pie diabético grado 5 de la clasificación de Wagner tras aplicar el Heberprot-P. Biotecnol Apl. 2010;27(2):113-15.




2020     |     www.medigraphic.com